科瑞产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@crene.cn

合作客户/Partner

当前位置：科瑞产品

vibegron

规格	价格	库存	数量
在线咨询大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：vibegron	纯度：98% min
CAS NO：1190389-15-1	溶解度：Soluble in DMSO
分子式：C₂₆H₂₈N₄O₃	包装：可按客户要求包装
分子量：444.526	贮存：-20ºC

质量控制

备注说明

Vibegron, also known as MK-4618, is a potent and selective Beta 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder (OAB). Vibegron has no unacceptable toxicity in preclinical species. Vibegron is currently in Phase 3 human clinical trials for the treatment of OAB. β3-adrenergic receptor (β3-AR) agonists were investigated as potential treatments for obesity and/or diabetes owing to their ability to induce lipolysis, thermogenesis, and antihyperglycemic activity in preclinical species.

参考文献

1: Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble S, Morriello GJ, Harper B, Moyes CR, Shen DM, Wang L, Ball RG, Fitzmaurice A, Frenkl T, Gichuru L, Ha SN, Hurley A, Jochnowitz N, Levorse D, Mistry S, Miller R, Ormes J, Salituro G, Sanfiz A, Stevenson A, Villa K, Zamlynny B, Green S, Struthers M, Weber AE. Discovery of Vibegron: A Potent and Selective Beta 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. J Med Chem. 2015 Dec 27. [Epub ahead of print] PubMed PMID: 26709102.